Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters











Database
Publication year range
1.
Arch Pediatr ; 20(6): 707-13, 2013 Jun.
Article in French | MEDLINE | ID: mdl-23628120

ABSTRACT

The mean age of first sexual intercourse is still around 17 in France, but a lot of teenagers are concerned by contraception before, with approximately 25% of sexually active 15-year-old girls. The contraceptive method must take into consideration some typical features of this population, as sporadic and non-planned sexual activity, with several sexual partners in a short period of time. In 2004, the "Haute Autorité de santé" has recommended, as first-line method, combined oral contraceptive (COC) pills, in association with male condoms. Copper-containing intrauterine contraceptive devices (IUCD) and etonogestrel-containing subcutaneous implant have been suggested but not recommended. However, oral contraceptive pill, as a user-based method, carries an important typical-use failure rate, because remembering taking a daily pill, and dealing with stop periods, may be challenging. Some easier-to-use method should be kept in mind, as 28-day COC packs, transdermal contraceptive patches, and vaginal contraceptive rings. Moreover, American studies have shown that long-acting reversible contraceptives (LARC), i.e. IUCD and implant, have many advantages for teenagers: very effective, safe, invisible. They seem well-fitted for this population, with high satisfaction and continuation rates, as long as side effects are well explained. Thus, LARC methods should be proposed more widely to teenagers. Anyway, before prescribing a contraceptive method, it is important to determine the specific situation of every teenager, to let them choose the method that they consider as appropriate in their own case, and to think about the availability of the chosen method. It is necessary to explain how to handle mistakes or misses with user-based contraceptive methods, and emergency contraception can be anticipated and prescribed in advanced provision. The use of male condoms should be encouraged for adolescents, with another effective contraceptive method, in order to reduce the high risk of sexually transmitted infections (STI) in this population.


Subject(s)
Adolescent Behavior , Contraception/methods , Abortion, Induced/statistics & numerical data , Administration, Cutaneous , Adolescent , Choice Behavior , Coitus , Condoms , Contraception, Postcoital , Contraceptive Agents/administration & dosage , Contraceptive Agents, Female/administration & dosage , Contraceptive Devices , Contraceptives, Oral/therapeutic use , Drug Implants , Female , France , Health Services Accessibility , Humans , Intrauterine Devices , Male , Patient Education as Topic , Patient Satisfaction , Physician-Patient Relations , Pregnancy , Sexual Partners , Sexually Transmitted Diseases/prevention & control
2.
Int J Chronic Dis ; 2013: 452134, 2013.
Article in English | MEDLINE | ID: mdl-26464845

ABSTRACT

The objective of this study was to evaluate the quality of life (QOL) of patients with deep infiltrating endometriosis (DIE) using EuroQOL (EQ-5D) and its correlation with symptoms and locations of endometriotic lesions. One hundred and fifty-nine patients referred for DIE from January 2011 to April 2011 were prospectively invited to complete questionnaires evaluating symptoms associated with endometriosis as well as the EQ-5D questionnaire and health state. Patients also had locations of DIE evaluated by clinical examination and magnetic resonance imaging (MRI). All 159 patients completed the questionnaires. Item response rate was 91.1%. The most intense symptoms were dysmenorrhea (7.1/10), painful defecation (6.3/10), and fatigue (6.0/10). Mean (SD) scores were 77 (14) for the EQ-5D questionnaire and 63.4 (21) for the health state. A relation was observed between the EQ-5D questionnaire and the presence of dysmenorrhea, dyspareunia, cyclic pelvic pain, painful defecation, and diarrhea or constipation. Vaginal and rectal infiltrations were significantly associated with altered EQ-5D and health state scores. The EQ-5D questionnaire is easy to complete and well related to symptoms of DIE. Rectal and vaginal infiltrations were found to be determinant factors of altered QOL by the EQ-5D questionnaire and health state.

3.
J Gynecol Obstet Biol Reprod (Paris) ; 40(7): 612-9, 2011 Nov.
Article in French | MEDLINE | ID: mdl-21733636

ABSTRACT

Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, are invalidating inflammatory affections, which evolve by relapse interrupted with clinical remission. Crohn's disease commonly affects young women in their reproductive years with a peak of incidence between 20 and 30. Infertility and sexual dysfunction are equivalent to that of the general population while they are increasing in patients with active IBD or after colorectal surgery. IBD are well controlled by medical treatments and the frequency of relapse during the pregnancy is similar to that of the non-pregnant IBD patients. The data concerning the risk of congenital malformations in IBD are contradictory. The risk of preterm delivery and low birth weight is significantly increased and correlated to the disease activity. When a medical treatment insures a quiescent disease before the pregnancy, it is advisable to continue it during the pregnancy because the benefits of controlled disease outweigh the risks of medication. IBD, possible perianal lesions and colorectal surgical interventions influence the mode of delivery, but the indication of caesarean section should primarily be governed by obstetric necessity. Preconceptional counseling seems desirable because of the risks during pregnancy, according to the disease activity, the surgical histories and the therapeutic agents.


Subject(s)
Cesarean Section/statistics & numerical data , Inflammatory Bowel Diseases/epidemiology , Pregnancy Complications/epidemiology , Premature Birth/epidemiology , Adult , Congenital Abnormalities/epidemiology , Congenital Abnormalities/etiology , Female , Gastrointestinal Agents/therapeutic use , Humans , Incidence , Infant, Low Birth Weight , Infant, Newborn , Infertility, Female/epidemiology , Infertility, Female/etiology , Inflammatory Bowel Diseases/complications , Inflammatory Bowel Diseases/drug therapy , Inflammatory Bowel Diseases/surgery , Pregnancy , Pregnancy Complications/etiology , Recurrence , Risk , Sexual Dysfunction, Physiological/epidemiology , Sexual Dysfunction, Physiological/etiology , Young Adult
4.
J Gynecol Obstet Biol Reprod (Paris) ; 40(6): 492-7, 2011 Oct.
Article in French | MEDLINE | ID: mdl-21733638

ABSTRACT

Anti-TNFα treatments have modified the medical care, the course and the quality of life of the patients with autoimmune rheumatic, cutaneous or bowel inflammatory diseases. On the other hand, these treatments may have potential severe side effects during pregnancy (congenital malformations, fetal infections). Actually, many pregnancies have been reported during anti-TNFα exposures, with good maternal and neonatal outcomes. The introduction or the discontinuation of these treatments will always have to be discussed with the specialist of the chronic disease and, ideally, during a preconceptional counselling. In gynecology, anti-TNFα drugs may offer a new safe and effective approach to treating patients with recurrent miscarriages or unexplained or failed in vitro fertilization cycles. On the other hand, these treatments significantly increase the risk for serious infections or viral reactivations and may promote gynaecological malignancies. An adapted gynaecological survey is necessary.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Gynecology/methods , Obstetrics/methods , Pregnancy Complications/drug therapy , Tumor Necrosis Factor-alpha/immunology , Anti-Inflammatory Agents/adverse effects , Anti-Inflammatory Agents/therapeutic use , Antibodies, Monoclonal/adverse effects , Female , Humans , Inflammatory Bowel Diseases/drug therapy , Infliximab , Pregnancy , Rheumatic Diseases/drug therapy , Tumor Necrosis Factor-alpha/antagonists & inhibitors
SELECTION OF CITATIONS
SEARCH DETAIL